Categories

 

Subscribe & Save

Forbes: NIH Trial Gives Surprising Boost To Chelation Therapy

Larry Husten  

Larry Husten, Contributor, Forbes

I'm a medical journalist covering cardiology news.


With a result that is likely to surprise and baffle much of the mainstream medical community, a large NIH-sponsored trial has turned up the first substantial evidence in support of chelation therapy for patients with coronary disease. Known as TACT (Trial to Assess Chelation Therapy),  the highly controversial trial was presented today at the AHA by Gervasio Lamas. The trial was sponsored by two NIH institutes, the National Center for Complementary and Alternative Medicine and the National Heart Lung and Blood Institute.

Full article here


No products

To be determined Shipping
$0.00 Total

Check out